American Society of Clinical Oncology (ASCO) 2017 Annual Meeting

June 27, 2017

Modified Citrus Pectin Shows Potential in Relapsed Prostate Cancer Patients, Study Suggests

News

Treament with modified citrus pectin (MCP), a nutritional supplement, led to promising results in men with recurrent prostate cancer, according to preliminary results from a Phase 2b trial. The study ... Read more

June 8, 2017June 8, 2017

ESSA Pharma Presents Early Results from Clinical Trial Testing EPI-506 in End-stage Prostate Cancer

News

ESSA Pharma‘s small molecule androgen receptor inhibitor, EPI-506 (ralaniten acetate), has shown a favorable safety and tolerability profile among end-stage prostate cancer patients enrolled in a Phase 1/2 trial, as ... Read more